louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06624111: Assessing Weight Bias Among Turkish Dietitians
Official title: Assessing Weight Bias Among Turkish Dietitians: Determinants and Impact on Professional Practice
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Weight Bias
Weight Stigma
Keywords: obesity
weight bias
weight stigma
fat-phobia
dietitian
Lead sponsor: Izmir Katip Celebi University
Sponsor class: OTHER
Collaborators: name: The Scientific and Technological Research Council of Turkey
First posted: 2024-10-02
Enrollment: 411
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study sample consisted of dietitians working Türkiye

Brief summary: The objective of this study was to examine weight bias among Turkish dietitians. and to investigate the effect of the patient's weight status on the dietitian's assessment and dietetic practice.

Detailed description: The dietitians were randomly assigned to an online case study with lactose intolerance, with all patient information identical except for the patient's weight and photograph. In one case there was a photograph of a woman with obesity and in the other a woman of normal weight. The objective of the case study was to evaluate how the body weight of a patient who consulted a dietitian for a reason unrelated to the body weight affected professional practices.

Eligibility criteria: Inclusion Criteria:

* Dietitians working in Turkiye

Exclusion Criteria:

* Pregnancy
* breastfeeding

Primary outcomes:
measure: Differences between dietitians' lifestyle recommendations among groups.
timeFrame: Baseline
Secondary outcomes:
measure: Differences between the biochemical status rated by dietitians between groups
timeFrame: Baseline
measure: Differences between the diet quality rated by dietitians between groups
timeFrame: Baseline
measure: Differences between dietatians' expectations regarding the patient's adherence to the diet between groups
timeFrame: Baseline
Other outcomes:
Locations:
city: Izmir
country: Turkey
facility: Izmir Katip Celebi University
Study officials:
References:
Clinical trial NCT03799211: Adherence to and Beliefs on Recommendations for Behavioral Treatment for Migraine
Official title: Adherence to and Beliefs on Recommendations for Behavioral Treatment for Migraine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Migraine
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2019-01-10
Enrollment: 76
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Migraine patients are oftentimes referred for evidence based behavioral therapies to prevent migraine. Yet, at follow-up visits, they report not seeing the behavioral therapist. This is a pilot feasibility acceptability study to assess whether motivational interviewing (MI) can be implemented in the headache center setting to help improve initiation and adherence to behavioral therapy for migraine. We will also assess patients' reasons for making/not making the appointment.


Eligibility criteria: Inclusion Criteria:

* Migraine diagnosis age 16+
* English speaking

Exclusion Criteria:

* Unable to read the questionnaire, no phone number

Primary outcomes:
measure: Percentage of Patients Who Made an Appointment for Behavioral Therapy
timeFrame: 3-6 Months
Secondary outcomes:
measure: Percentage of Participants Who Attended Appointments
timeFrame: 3-6 Months
measure: Percentage of Participants Who Initiated Appointments
timeFrame: Month 3-4 post-recruitment
measure: Mean Reported Importance of Managing Migraine
timeFrame: First Follow-up Call (1 month post baseline) conducted only for the Arm/Group "Motivational Interviewing" and Last Follow-up Call (3-4 months post baseline)
measure: Mean Reported Confidence in Managing Migraines
timeFrame: First Follow-up Call (1 month post baseline) conducted only for the Arm/Group "Motivational Interviewing" and Last Follow-up Call (3-4 months post baseline)
measure: Mean Reported Confidence in Behavioral Therapy
timeFrame: First Follow-up Call (1 month post baseline) conducted only for the Arm/Group "Motivational Interviewing" and Last Follow-up Call (3-4 months post baseline)
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone
state: New York
Study officials:
affiliation: NYU Langone
name: Mia Minen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01806311: Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg
Official title: An Open-label, Multiple-dose, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of amlodipine10mg and candesartan32mg in Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hypertension
Keywords: Pharmacokinetics
Safety
Male
Lead sponsor: HanAll BioPharma Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2013-03-07
Enrollment: 36
Sex: MALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Clinical trial to evalate the pharmacokinetic interactions and safety between single dose of amlodipine10mg and candesartan32mg and combiation dose amlodipine10mg with candesartan32mg in healthy male volunteers.


Eligibility criteria: Inclusion Criteria:

1. Healthy male, Age 20 to 45
2. Subject must be willing and able to provide written informed consent to the study.

Exclusion Criteria:

1. History of any significant sickness, liver system, gall bladder system, kidney, nerve system, respiratory system, blood tumor, endocrine system, urinary system, mental disease, muscloskeletal system, immunity system, the ear, nose and throat system and cardiovascular system.
2. History of any significant gastrointestinal system and surgery of gastrointestinal.
3. History of any significant hypersensitivity to amlodipine, candesartan, aspirin, antibiotic.
4. Over 10 tobaccos a day.
5. Other condition which in the opinion of the investigator preclude endrollment into the study.

Primary outcomes:
measure: Part A : AUC, Cmax of Candesartan
timeFrame: Over a 24-hour sampling period
measure: Par B : AUC, Cmax of Amlodipine
timeFrame: Over a 24-hour sampling period
Secondary outcomes:
measure: PartA: Cmin, tmax, CL/F of Candesartan
timeFrame: Over a 24-hour sampling period
measure: PartB: Cmin, tmax, CL/F of Amlodipine
timeFrame: Over a 24-hour sampling period
Other outcomes:
Locations:
city: Daejeon
country: Korea, Republic of
facility: Chungnam national university hospital,clinical trial center
state: Chungcheongbul-do
Study officials:
affiliation: Chungnam national university hospital, Clinical trial center
name: Jang Hee Hong, Associate Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03483311: Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy
Official title: Estimation of Tissue Level of Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy: a Case-control Study.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Psoriasis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-03-30
Enrollment: 30
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: • Assessment of tissue level of resolvin D1 in psoriasis in comparison to its level in healthy controls in order to verify its role in the pathogenesis of psoriasis.


Eligibility criteria: Inclusion Criteria:

* Patients with psoriasis (adults and children above 12years)
* Both sexes.
* New cases or cases not receiving any treatment for at least 3 months ago.

Exclusion Criteria:

* Any contraindication to phototherapy treatment (e.g. Photosensitizing creams or medications, past skin cancer, especially melanoma, etc...)
* Erythrodermic and pustular psoriasis.
* History of autoimmune diseases or other systemic diseases (e.g. Alzheimer's disease, fibromyalgia, cystic fibrosis)

Primary outcomes:
measure: Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB.
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Maha Fathy Elmasry
Study officials:
affiliation: Cairo University
name: Maha Elmasry
role: PRINCIPAL_INVESTIGATOR
References:
citation: Elmasry MF, Hassan E, Rashed LA, Abdel Halim DM. Role of resolvin D1 in psoriasis before and after narrowband ultraviolet B phototherapy: A case-control study. Dermatol Ther. 2021 Mar;34(2):e14879. doi: 10.1111/dth.14879. Epub 2021 Feb 21.
Clinical trial NCT00436111: Characterization of Macroprolactinemia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hyperprolactinemia
Keywords: hyperprolactinemia
autoantibody
Lead sponsor: Kansai Medical University
Sponsor class: OTHER
First posted: 2007-02-16
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: DEFINED_POPULATION
Time perspective: RETROSPECTIVE

Brief summary: The purpose of this study is to clarify the nature of macroprolactin which has recently been highlighted because of the high prevalence and a diagnostic pitfall of hyperprolactinemia. The results of this study are beneficial for the patients to whom unnecessary medications and unnecessary radiological examinations have been performed.

We used the remained serum samples taken for routine prolactin determination during the past several years. Since the blood was basically taken to examine the causes of hyperprolactinemia and only remained serum samples were used for this study, the Ethics Committee of Kobe City General Hospital judged that it was not required to obtain approval number.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of hyperprolactinemia

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Osaka
country: Japan
facility: Kansai Medical University
Study officials:
affiliation: Department of Pharmacology, Kansai Medical University
name: Naoki Hattori, M.D., Ph.D.
role: STUDY_CHAIR
References:
citation: Hattori N, Nakayama Y, Kitagawa K, Ishihara T, Saiki Y, Inagaki C. Anti-prolactin (PRL) autoantibody-binding sites (epitopes) on PRL molecule in macroprolactinemia. J Endocrinol. 2006 Aug;190(2):287-93. doi: 10.1677/joe.1.06871.
citation: Hattori N, Ikekubo K, Nakaya Y, Kitagawa K, Inagaki C. Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies. J Clin Endocrinol Metab. 2005 May;90(5):3036-44. doi: 10.1210/jc.2004-1600. Epub 2005 Feb 1.
citation: Hattori N, Inagaki C. Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex. J Clin Endocrinol Metab. 1997 Sep;82(9):3107-10. doi: 10.1210/jcem.82.9.4250.
citation: Hattori N, Ishihara T, Ikekubo K, Moridera K, Hino M, Kurahachi H. Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia. J Clin Endocrinol Metab. 1992 Nov;75(5):1226-9. doi: 10.1210/jcem.75.5.1430082.
Clinical trial NCT06644911: Obesity Doppler in Term Pregnancy
Official title: The Effect of Maternal Obesity on Umbilical and Uterine Artery Doppler in Term Pregnancy : a Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Doppler Measurement of Uterine Artery
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-10-16
Enrollment: 240
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women

Brief summary: Maternal obesity is an epidemic in the developed world like Egypt. There are many pregnancy-associated complications including pre-eclampsia, gestational diabetes, and increased rates of septic wound after cesarean delivery. As a potential explanation of the etiology of complications due to maternal obesity, the role of endothelial dysfunction in the systemic and peripheral vasculatures has been hypothesized. It has been proposed that some adverse pregnancy outcomes in obese patients may be mediated by placental insufficiency. Utero-placental insufficiency is typically associated with fetal growth restriction and low birth weight.

Umbilical and uterine artery Doppler is widely accepted as a useful tool for monitoring high-risk pregnancies.

Normally, uterine artery vascular impedance gradually decreases until the late mid-trimester, owing to the establishment of a low-resistance placental circulation. Obesity has little impact on uterine vascular changes reflected by the early uterine artery PI. However, in the second trimester, extreme obesity appears to impair the normal continued drop in uterine vascular resistance. Many studies have examined the relationship between BMI and Doppler changes in high-risk pregnancies, but few have addressed these changes in low-risk pregnancies.


Eligibility criteria: Inclusion Criteria:

1. Singleton pregnancy
2. Gestational age ≥ 37 weeks
3. Absence of fetal structural abnormalities
4. Absence of maternal comorbidities and/or complications.
5. Obese women (BMI ≥ 30 kg/m2) \[11\].
6. Normal weight (BMI 18.5-24.9) \[11\].

Exclusion Criteria:

1. Placenta previa
2. Women with antepartum hemorrhage.
3. Smokers and alcohol consumers
4. Preeclampsia
5. Diabetes mellitus
6. Women need urgent termination of pregnancy.

Primary outcomes:
measure: The difference between uterine and umbilical artery Doppler resistant index
timeFrame: at 37 weeks of pregnancy
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Woman's Health Hospital - Assiut university
Study officials:
References:
Clinical trial NCT02886611: Limbal Stem Cell Deficiency of Genetic Origin: Genotype-phenotype Correlation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Limbus Corneae
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2016-09-01
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with decreased visual acuity of corneal origin will be selected and genetic analysis will be performed.

Brief summary: The study aims at searching for a genotype-phenotype correlation in patients with a genetic pathology of the ocular surface, in order to identify genetic abnormalities associated with the most severe clinical situations.


Eligibility criteria: Inclusion Criteria:

* genetic pathology of ocular surface

Exclusion Criteria:

* Agonal glaucoma
* Low vision mostly related to retinal pathology
* Pregnant or breast feeding patient

Primary outcomes:
measure: Genotype-phenotype Correlation
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation Ophtalmologique Adolphe de Rothschild
Study officials:
affiliation: Hôpital Fondation Adolphe de Rothschild
name: Anna GEMAHLING, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hôpital Bichat (AP-HP)
name: Eric GABISON, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hopital Necker-enfants malades (AP-HP)
name: Dominique BREMOND-GIGNAC, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02028611: Comparison of Gray-scale Inverted Rib Series With Conventional Ones in Rib Fracture Detection by Emergency Physicians and Medical Students
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Rib Fracture
Keywords: Rib fracture
Inverted grayscale
Lead sponsor: Hanyang University
Sponsor class: OTHER
First posted: 2014-01-07
Enrollment: 55
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Emergency medicine residents

Brief summary: There were many studies which examined the availability of inverted gray-scale chest X-ray for increasing the detection of lung nodules. In emergency medicine, rib fracture is an important part for patient's disposition, so investigators designed this study to evaluate the availability of inverted gray-scale chest X-ray for the detection of rib fracture.


Eligibility criteria: Inclusion Criteria:

* Emergency resident who want to participate

Exclusion Criteria:

* Emergency resident who does not want to participate

Primary outcomes:
measure: Sensitivity of detection for rib fracture
timeFrame: up to 12 weeks
Secondary outcomes:
measure: Accuracy for rib fracture
timeFrame: up to 12 weeks
Other outcomes:
Locations:
Study officials:
References:
citation: Park JB, Cho YS, Choi HJ. Diagnostic accuracy of the inverted grayscale rib series for detection of rib fracture in minor chest trauma. Am J Emerg Med. 2015 Apr;33(4):548-52. doi: 10.1016/j.ajem.2015.01.015. Epub 2015 Jan 20.
Clinical trial NCT06408311: Safety of ENC-201-CED ENCRT
Official title: A Safety and Tolerability Study of ENC=201-CED in Participants With Type 1 Diabetes Receiving Islet Infusion
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Diabetes Mellitus, Type 1
Keywords: Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism
Islet Infusion
Pancreas Transplant
Lead sponsor: Encellin
Sponsor class: INDUSTRY
Collaborators: name: resCON Research
First posted: 2024-05-10
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: The purpose of the study is to evaluate the safety and tolerability of ENC-201-CED in a subcutaneous space in patients with Type I diabetes.


Eligibility criteria: Inclusion Criteria:

* Candidates must satisfy site's eligibility for standard of care islet infusion.

Exclusion Criteria:

* Candidates are excluded based on the site's criteria for standard of care islet infusion.

Primary outcomes:
measure: Safety
timeFrame: Day 1 through Day 134
Secondary outcomes:
measure: Containment
timeFrame: post Day 120
measure: Engraftment
timeFrame: post Day120
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: UHN
state: Ontario
city: Montréal
country: Canada
facility: McGill University Health Centre
state: Quebec
Study officials:
affiliation: Encellin
name: Grace Wei, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00243711: A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Investigational Lubricant Eye Drop
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Dry Eye
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2005-10-25
Enrollment: 286
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The efficacy, safety and acceptability of an investigational lubricant eye drop in subjects with dry eye will be evaluated in comparison with currently-available lubricant eye drops.


Eligibility criteria: Inclusion Criteria:

* Mild, Moderate, or Severe Dry Eye Symptoms and current eye drop use;
* Reduced tear stability or tear production

Exclusion Criteria:

* NONE

Primary outcomes:
measure: Dry Eye Symptoms
Secondary outcomes:
measure: Ocular surface damage, tear stability, tear production
Other outcomes:
Locations:
city: Warrensburg
country: United States
state: Missouri
Study officials:
affiliation: InSight Eyecare
name: Mark Curtis, O.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06993311: Real World Evidence of Xen45 Gel Implant in Pseudoexfoliation Glaucoma
Official title: Four-year Outcomes of Minimally Invasive XEN Gel Stent Implantation in Pseudoexfoliation Glaucoma: Real World Evidence
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pseudoexfoliation Syndrome
Pseudoexfoliation Glaucoma in Both Eyes
Open Angle Glaucoma
Keywords: Xen
Lead sponsor: Xerencia de Xestión Integrada de Ferrol
Sponsor class: OTHER
Collaborators: name: University Hospital Complex of Santiago de Compostela
First posted: 2025-05-28
Enrollment: 350
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Data will be collected for all patients with PXFG, POAG and other secondary OAG, who underwent surgery from 2018 to 2022, at 2 terciary care academic ophthalmology centers (University Hospital Complex of Ferrol and University Hospital Complex of Santiago de Compostela, Spain) by 10 surgeons.

Brief summary: The Xen implant is an ab interno device that has been shown to be effective in reducing intraocular pressure in several types of glaucoma, although the evidence in pseudoexfoliative glaucoma is limited. The present retrospective observational study aims to increase knowledge about the long-term effectiveness and safety of the implant in pseudoexfoliative glaucoma. Researchers will compare the results with data from patients with open-angle glaucoma.


Eligibility criteria: Inclusion Criteria:

Data will be collected for all patients with pseudoexfoliation glaucoma (PXFG), ocular hypertension (OHT) and pseudoexfoliation syndrome, POAG and other secondary open angle glaucoma (OAG) diagnosed, who underwent surgery from 2018 to 2022.

Patients should be candidates for filtering glaucoma surgery for the following indications:

* uncontrolled intraocular pressure (IOP)
* intolerance or non-adherence to topical treatment
* glaucoma progression despite topical therapy
* surgical cataract patients undergoing phacoemulsification, who were treated with two or more hypotensive drugs and wished to withdraw the medication due to side effects and/or discomfort of the treatment.

Refractory glaucoma and eyes with previous filtering surgery, previous laser treatments or micropulse transscleral cyclophotocoagulation will be also included.

Exclusion Criteria:

* Patients with follow up less than 12 months.
* Patients with end-stage glaucoma, uveitic and angle closure glaucoma.

Primary outcomes:
measure: INTRAOCULAR PRESSURE
timeFrame: 12-48 months
Secondary outcomes:
measure: NUMBER OF TREATMENTS
timeFrame: 12-48 months
measure: BEST CORRECTED VISUAL ACUITY
timeFrame: 12-48 months
measure: RETINAL NERVE FIBER LAYER
timeFrame: 12-48 months
measure: RATES OF REINTERVENTION
timeFrame: 12-48 months
measure: INCIDENCE OF TREATMENT ADVERSE EVENTS
timeFrame: 12-48 months
measure: PRESERVATIVES EXPOSURE
timeFrame: 12-48 months
Other outcomes:
Locations:
city: Ferrol
country: Spain
facility: Sara Pose-Bazarra
Study officials:
References: